The prevalence rates of TP53 mutations in CLL, MCL, and (D)LBCL have been reported to range from approximately 10% to 30%, which aligns with our findings and those of other studies [2, 4, 8]. The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.